Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin

Phase 1

Completed

Conditions: Solid Tumors
Advanced Cancer

Interventions: Drug: AMG 531
Drug: Carboplatin
Drug: Adriamycin
Drug: Ifosfamide

First Posted Date: 2005-09-07

Last Posted Date: 2014-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 55

Registration Number: NCT00147225

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site

Phase 2

Terminated

Conditions: Carcinoma of Unknown Primary

First Posted Date: 2005-09-07

Last Posted Date: 2008-01-10

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT00148135

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Determination of Carboplatin's Optimal Plasmatic Exposure

Not Applicable

Completed

Conditions: Neoplasms

First Posted Date: 2005-09-05

Last Posted Date: 2009-03-18

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 400

Registration Number: NCT00145028

Locations: 🇫🇷
CHU A. Michallon, Grenoble, France
🇫🇷
Centre Oscar Lambert, Lille, France
🇫🇷
Centre Paul Papin, Angers, France

and more 12 locations

Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2005-08-30

Last Posted Date: 2013-06-26

Lead Sponsor: Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center

Target Recruit Count: 30

Registration Number: NCT00138242

Locations: 🇺🇸
Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle, Washington, United States

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Phase 3

Completed

Conditions: Lymphoma, Large-Cell, Diffuse

Interventions: Drug: Rituximab
Drug: Cisplatine
Drug: Etoposide
Drug: Carboplatine
Drug: Cytosine Arabinoside
Drug: Ifosfamide + Mesna
Drug: Dexamethasone
Procedure: Autologous Stem Cell Transplantation
Drug: BCNU
Drug: Cytarabine
Drug: Melphalan

First Posted Date: 2005-08-30

Last Posted Date: 2019-08-28

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 481

Registration Number: NCT00137995

Locations: 🇮🇱
Israel Society of Hematology, Tel-Hashomer, Israel
🇨🇭
Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland
🇫🇮
Hospital district of south west Finland, Turku, Finland

and more 7 locations

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumours

Interventions: Drug: SB-715992
Drug: carboplatin

First Posted Date: 2005-08-29

Last Posted Date: 2017-09-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT00136578

Locations: 🇬🇧
GSK Investigational Site, Newcastle Upon Tyne, Northumberland, United Kingdom

Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2005-08-26

Last Posted Date: 2015-01-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 68

Registration Number: NCT00136175

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-08-25

Last Posted Date: 2009-12-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00134706

Locations: 🇺🇸
Lowell General Hospital, Lowell, Massachusetts, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Wentworth Douglass Hospital, Dover, New Hampshire, United States

and more 3 locations

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

Phase 1

Terminated

Conditions: Esophageal Cancer
Gastric Cancer
Tumors

First Posted Date: 2005-08-17

Last Posted Date: 2016-02-15

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 50

Registration Number: NCT00130936

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4

Phase 2

Completed

Conditions: Sarcoma, Soft Tissue

First Posted Date: 2005-08-16

Last Posted Date: 2009-04-02

Lead Sponsor: Cooperative Weichteilsarkom Study Group

Target Recruit Count: 90

Registration Number: NCT00130858

Locations: 🇩🇪
Klinikum der Universität Kiel, Kiel, Germany
🇩🇪
Zentralkrankenhaus Bremen, Bremen, Germany
🇩🇪
Universitätsklinik der technischen Universität Dresden, Dresden, Germany

and more 30 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy